
Progyny (PGNY) Stock Forecast & Price Target
Progyny (PGNY) Analyst Ratings
Bulls say
Progyny Inc. is well-positioned for continued growth within the expanding fertility insurance market, which is projected to potentially double in size, bolstered by the company's leadership and market share gains. The company is anticipating an increase in membership numbers for 2025 compared to 2024, supported by strong momentum in its selling season and favorable survey results indicating rising coverage rates among employers. Furthermore, Progyny's ability to attract new clients—adding 71 in 2024 and 80 in 2023—has led to significant growth in covered lives, demonstrating a robust demand for its comprehensive benefits solutions in fertility and women's health.
Bears say
Progyny Inc. is facing a negative outlook primarily due to a significant revision in revenue estimates, which has been lowered by 13.6% for 2025 to $1.2 billion from $1.4 billion, largely attributed to the loss of a key client that constituted 12% of revenue year-to-date. Additionally, the company's first-time guidance for 2028 of 20% revenue and 25% EBITDA growth appears to set expectations unreasonably high, especially in light of current competitive pressures and potential economic headwinds. Furthermore, projected margin pressures may arise from the loss of accounts that operated at lower margins, leading to increased concerns regarding utilization rates and the company's ability to maintain its competitive position in the market.
This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares